Clinical trial

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

NCT00546364

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2008-02-01

PhasePHASE2

Study timeline

Study start (unknown)2008-02-01Date precision: month

Registry last updated2016-03-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Neoplasmsunresolved

Interventions

Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2DRUG

Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2DRUG

Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2DRUG

Sponsors & collaborators

R-Pharmlead sponsor

Mapped research locations

PhiladelphiaPennsylvania, United States2 Baton RougeLouisiana, United States2 AkronOhio, United States2 HoustonTexas, United States1 ChicagoIllinois, United States1 BaltimoreMaryland, United States1 MiamiFlorida, United States1 ColumbusOhio, United States1 Washington D.C.District of Columbia, United States1 JacksonvilleFlorida, United States1 AustinTexas, United States1 CharlestonSouth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00546364 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.